Abstract: To establish a disease risk prediction model for the newborn screening system of inherited metabolic diseases by artificial intelligence technology. This was a retrospectively study. Newborn screening data (5 907 547) from February 2010 to May 2019 from 31 hospitals in China and verified data (=3 028) from 34 hospitals of the same period were collected to establish the artificial intelligence model for the prediction of inherited metabolic diseases in neonates. The validity of the artificial intelligence disease risk prediction model was verified by 360 814 newborns screening data from January 2018 to September 2018 through a single-blind experiment. The effectiveness of the artificial intelligence disease risk prediction model was verified by comparing the detection rate of clinically confirmed cases, the positive rate of initial screening and the positive predictive value between the clinicians and the artificial intelligence prediction model of inherited metabolic diseases. A total of 3 665 697 newborns screening data were collected including 3 019 cases positive data to establish the 16 artificial intelligence models for 32 inherited metabolic diseases. The single-blind experiment (=360 814) showed that 45 clinically diagnosed infants were detected by both artificial intelligence model and clinicians. A total of 2 684 cases were positive in tandem mass spectrometry screening and 1 694 cases were with high risk in artificial intelligence prediction model of inherited metabolic diseases, with the positive rates of tandem 0.74% (2 684/360 814)and 0.46% (1 694/360 814), respectively. Compared to clinicians, the positive rate of newborns was reduced by 36.89% (990/2 684) after the application of the artificial intelligence model, and the positive predictive values of clinicians and artificial intelligence prediction model of inherited metabolic diseases were 1.68% (45/2 684) and 2.66% (45/1 694) respectively. An accurate, fast, and the lower false positive rate auxiliary diagnosis system for neonatal inherited metabolic diseases by artificial intelligence technology has been established, which may have an important clinical value.

The significance of machine learning in neonatal screening for inherited metabolic diseases

Integration of Machine Learning Techniques as Auxiliary Diagnosis of Inherited Metabolic Disorders - Promising Experience with Newborn Screening Data.

[Screening for neonatal inborn errors of metabolism by electrospray ionization-tandem mass spectrometry and follow-up].

Application of a Next-Generation Sequencing (NGS) Panel in Newborn Screening Efficiently Identifies Inborn Disorders of Neonates

Current Problems and Prospect on Tandem Mass Spectrometry Based Newborn Inherited Metabolic Diseases Screening

A Multicenter Prospective Study of Next-Generation Sequencing-Based Newborn Screening for Monogenic Genetic Diseases in China

Application of Region 4 Stork system in the neonatal screening for very long chain acyl-CoA dehydrogenase deficiency by tandem mass spectrometry

Genetic Identification of Pathogenic Variations of the DMD Gene: a Retrospective Study from 10,481 Neonatal Patients Based on Next-Generation Sequencing Data

Newborn Screening for Inherited Metabolic Diseases Using Tandem Mass Spectrometry in China: Outcome and Cost-Utility Analysis

Establishment of an auxiliary diagnosis system of newborn screening for inherited metabolic diseases based on artificial intelligence technology and a clinical trial

Next-generation sequencing based newborn screening and comparative analysis with MS/MS

Screening of 1.17 million newborns for inborn errors of metabolism using tandem mass spectrometry in Shanghai, China: A 19-year report

Machine Learning: A Potential Therapeutic Tool to Facilitate Neonatal Therapeutic Decision Making

Opportunities and challenges in machine learning-based newborn screening-A systematic literature review

[A prospective study of genetic screening of 2 060 neonates by high-throughput sequencing]

Spectrum Analysis of Inherited Metabolic Disorders for Expanded Newborn Screening in a Central Chinese Population

Newborn Screening for Inborn Errors of Metabolism by Next-Generation Sequencing Combined with Tandem Mass Spectrometry

Screening for Inherited Metabolic Diseases Using Gas Chromatography-Tandem Mass Spectrometry (Gc-Ms/ms) in Sichuan, China

Reducing False-Positive Results in Newborn Screening Using Machine Learning

A pilot study of expanded newborn screening for 573 genes related to severe inherited disorders in China: results from 1,127 newborns

Current Status and Prospects of Screening for Newborn Hereditary Metaboolic Disease